Thompson Davis & CO. Inc. Grows Stake in AxoGen, Inc. (AXGN)
Thompson Davis & CO. Inc. raised its holdings in shares of AxoGen, Inc. (NASDAQ:AXGN) by 575.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,750 shares of the medical equipment provider’s stock after buying an additional 5,750 shares during the quarter. Thompson Davis & CO. Inc.’s holdings in AxoGen were worth $113,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the company. Bank of America Corp DE grew its holdings in shares of AxoGen by 8.7% in the first quarter. Bank of America Corp DE now owns 10,183 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 814 shares during the period. Parametric Portfolio Associates LLC grew its holdings in shares of AxoGen by 0.9% in the first quarter. Parametric Portfolio Associates LLC now owns 10,843 shares of the medical equipment provider’s stock valued at $113,000 after purchasing an additional 93 shares during the period. Campbell & CO Investment Adviser LLC grew its holdings in shares of AxoGen by 3.2% in the first quarter. Campbell & CO Investment Adviser LLC now owns 11,055 shares of the medical equipment provider’s stock valued at $116,000 after purchasing an additional 341 shares during the period. TFS Capital LLC purchased a new stake in shares of AxoGen in the first quarter valued at about $120,000. Finally, Knott David M purchased a new stake in shares of AxoGen in the first quarter valued at about $142,000. 66.77% of the stock is owned by institutional investors and hedge funds.
Shares of AxoGen, Inc. (NASDAQ AXGN) remained flat at $18.15 during midday trading on Friday. 180,774 shares of the stock traded hands. The company’s market cap is $603.31 million. The firm has a 50-day moving average of $16.11 and a 200-day moving average of $13.73. AxoGen, Inc. has a 12 month low of $7.65 and a 12 month high of $18.50.
AxoGen (NASDAQ:AXGN) last announced its earnings results on Wednesday, August 2nd. The medical equipment provider reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. AxoGen had a negative net margin of 27.50% and a negative return on equity of 114.64%. The firm had revenue of $15.20 million during the quarter, compared to the consensus estimate of $14.40 million. During the same quarter in the previous year, the company posted ($0.09) EPS. The firm’s revenue for the quarter was up 46.2% on a year-over-year basis. On average, equities research analysts predict that AxoGen, Inc. will post ($0.31) earnings per share for the current fiscal year.
A number of brokerages recently issued reports on AXGN. BidaskClub lowered shares of AxoGen from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. Leerink Swann began coverage on shares of AxoGen in a report on Monday, July 31st. They issued an “outperform” rating and a $22.00 price objective for the company. Wedbush reissued an “outperform” rating and issued a $14.00 price objective (down previously from $17.00) on shares of AxoGen in a report on Friday, May 19th. Cantor Fitzgerald began coverage on shares of AxoGen in a report on Thursday, June 29th. They issued an “overweight” rating and a $18.00 price objective for the company. Finally, ValuEngine raised shares of AxoGen from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $15.90.
ILLEGAL ACTIVITY NOTICE: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/09/10/thompson-davis-co-inc-grows-stake-in-axogen-inc-axgn.html.
AxoGen Company Profile
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Stock Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related stocks with our FREE daily email newsletter.